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Drug-induced polyuria and polydipsia have been
recognized with increasing frequency during the past
five years. Several drugs, such as lithium, had been
in use for many years without recognition of these
toxic side effects, although clinical symptoms appear
in almost one out of every ten patients treated with
lithium for manic-depressive disorders [1]. Other
drugs, such as demeclocycline, cause symptoms only
after prolonged use or in high concentrations which
are not seen in the usual clinical setting [2]. Still other
agents, such as the anesthetic methoxyflurane, have
had their toxicity recognized almost immediately af-
ter their introduction [3, 4]. Finally, some drugs are
either too new, such as glipizide [5] and glyburide [6],
or have too low orders of toxicity, such as dextropro-
poxyphene [7], to have had their side effects on water
metabolism widely appreciated.
Patients with drug-induced diabetes insipidus pre-
sent with complaints of polyuria, polydipsia or both.
It is important to distinguish between primary poly-
dipsia (central stimulation of thirst) and primary
polyuria (central or nephrogenic diabetes insipidus)
in patients with drug-induced defects in water metab-
olism because some of these drugs (e.g., lithium) are
psychoactive, and some of the diseases for which they
are used can be associated with psychogenic poly-
dipsia. While direct stimulation of thirst has been
suggested as contributing to the polydipsia associated
with several known renal concentrating defects, in-
cluding hypokalemia [8, 9], hypercalcemia [8] and
lithium [10], there is no known therapeutic agent
which produces polydipsia and polyuria solely by
a direct effect on thirst. Ordinarily, patients with
primary polydipsia (and secondary polyuria) can
be distinguished from patients with primary polyuria
(and secondary polydipsia) by serial observation of
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the urine osmolality [111 before and after 12 to 18 hr
of water deprivation (or a 5% loss in body wt). In
response to this maximum stimulation of endogenous
antidiuretic hormone (ADH), normal subjects will
concentrate their urine >850 mOsm/kg, and most
patients with primary polydipsia alone will concen-
trate their urine >450 mOsm/kg; there should be no
further increase in urine osmolality after administra-
tion of exogenous ADH following dehydration. Many
patients with severe or prolonged primary polydipsia
will require reconstitution of their medullary osmolar
gradient with water restriction, and with electrolyte
and urea replacement over several days before
achieving a normal response to dehydration (>850
mOsm/kg).
If the patient is unable to concentrate urine ade-
quately in response to water deprivation, then a diag-
nosis of diabetes insipidus can be made. Patients with
severe or complete nephrogenic diabetes insipidus
(hereditary or drug-induced) will not concentrate
their urine above plasma and will have no further
response to exogenous vasopressin [1, Il, 12],
whereas patients with pituitary (central) diabetes in-
sipidus will show some additional response to ex-
ogenous vasopressin following dehydration. (If the
response is >850 mOsm/kg, pure central diabetes
insipidus is present; if the response is <800
mOsm/kg, additional defects in water metabolism,
such as a loss of the medullary gradient, should be
considered.) It should be emphasized, however, that
such standard concentrating tests will not always
distinguish between patients with psychogenic poly-
dipsia (without reconstitution) and partial (incom-
plete) nephrogenic diabetes insipidus, since both
groups may concentrate urine osmolality above
plasma following adequate dehydration and neither
may respond further to exogenous vasopressin. These
disorders can be distinguished by reconstitution of
the medullary osmolar gradient (as above), or by
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prolonged administration (one to three days) of vaso-
pressin tannate in oil. Patients with psychogenic
polydipsia will concentrate their urine further and
may develop hyponatremia during this treatment.
In this review of drug-induced nephrogenic diabe-
tes insipidus, we will focus on the mechanisms by
which the drugs interfere with normal renal water
metabolism. In some cases, there are several clearly
defined sites of action for the drug. In other cases,
there is insufficient information to define any site
of action with certainty. However, in order to ap-
preciate the possible sites of action, it is necessary
to consider the normal mechanisms which control
water metabolism, particularly those related to ADH.
These mechanisms (Fig. I, right) are described
in detail elsewhere in this symposium, and can be
conveniently divided into two groups: central and
nephrogenic. The central mechanisms concern the
synthesis, storage and release of ADH; the nephro-
genic mechanisms concern the action of ADH to
promote water reabsorption. A defect in any of these
mechanisms can be responsible for polyuria. By defi-
nition, defects which solely involve the central mech-
anisms (central diabetes insipidus) can be corrected
completely by exogenous ADH administration. On
the other hand, defects which cannot be corrected by
the exogenous administration of ADH under hydro-
penic conditions must at least involve some nephro-
genic mechanism. (Note that a failure to respond to
exogenous ADH does not exclude an additional de-
fect in the central mechanisms.)
The nephrogenic mechanisms can be further sub-
divided into those which relate to the production and
maintenance of an osmotic gradient, and those which
concern the utilization of that gradient (Table I). In
Table I. Renal mechanisms required for water clearance
A. Production of osmotic gradient
I. Sufficient functioning nephrons
2. Sufficient NaCI delivery to medullary segments
3. Sufficient NaCI transport in medullary segments
4. Sufficient urea trapping in renal medulla
B. Utilization of osmotic gradient
I. Appropriate renal blood flow
2. Appropriate ADH action on collecting ducts
3. Appropriate response to ADH by collecting ducts
4. Appropriate urine flow rate
humans, the former are generally evaluated indirectly
by measuring: a) the blood urea nitrogen (BUN)
concentration and the creatinine clearance (Cer), b)
the electrolyte-free water clearance (CH2O) and the
minimum urine osmolality (Umin) under steady-
state water diuresis, c) the total electrolyte excretion
(UNa+K) under hydropenic conditions and d) the
negative electrolyte-free water clearance (TCH2O) af-
ter ADH and hypertonic saline administration. If
these tests are normal, it is assumed that electrolyte
(and urea) delivery and transport are grossly ade-
quate to generate and maintain an osmotic gradient,
and that any defect in the response to exogenous
ADH probably lies in the response of the collecting
ducts to ADH. (Note that these indirect in vivo tests
cannot rigidly exclude defects in the maintenance of
an osmotic gradient, or more subtle defects in gra-
dient generation.)
Defects in the interaction between ADH and the
collecting duct cannot be evaluated further in hu-
mans. However, both in vivo and in vitro animal
models can be used to establish the defective site(s)
more precisely (Fig. 1, left). The first level of analysis
is simply a comparison of the physiological actions of
Fig. 1. Mechanism of action of ADH (see
text). ADH = antidiuretic hormone; AlP =
adenosine triphosphate; AMP = adenosine
monophosphate; cAMP = cyclic adenosine
3', 5'-monophosphate; PPi = pyrophosphate;
ATPase = adenosine triphosphatase; PDEase
= cAM P phosphodiesterase. (Reprinted with
permission from [17].)
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ADH and cyclic adenosine-3', 5'-monophosphate
(cAMP) in the presence of the inhibitor. Since cAMP
mediates the response to ADH [13], a defect in the
ADH response with no defect in the cAMP response
localizes the defect to those processes prior to cAMP
generation, such as interaction of ADH with its mem-
brane receptor, activation of adenylate cyclase and
utilization of adenosine triphosphate (ATP). On the
other hand, a failure to respond to cAMP indicates at
least a defect after cAMP generation, such as protein
k inase activation, phosphodiesterase (PDEase) acti-
vation and protein phosphorylation. (Note that the
commonly used dibutyryl cAMP analog of cAMP
may or may not penetrate lipid membranes into the
cell more readily than cAMP, but it does have some
PDEase inhibitory activity [14],) Further analysis
depends on various in vitro biochemical assays for
tissue concentrations of cAMP; for tissue ATPase,
PDEase and protein kinase activities; and for altera-
tions in phosphoprotein metabolism. Thus, a com-
bination of indirect tests in humans and more direct
tests in animal model systems can be used with rea-
sonable precision to localize the site(s) of action of
the various drugs which produce nephrogenic dia-
betes insipidus.
Lithium
Lithium was the first drug whose mechanism of
action was studied extensively in humans and in ani-
mal models. Following several case reports of a re-
versible polyuria unresponsive to vasopressin in pa-
tients receving lithium [15, 16], Singer, Rotenberg
and Puschett [12] reported three patients with lith-
ium-induced polyuria who demonstrated normal ex-
cretion of electrolyte-free water (CH2O) with marked
impairment of electrolyte-free water reabsorption
(ICH20) after administration of hypertonic saline and
vasopressin. In a study of 96 consecutive patients
receiving lithium carbonate, Forrest et al [1] reported
polydipsia in 40% and polyuria in 12% of these pa-
tients. Maximum concentrating ability after dehydra-
tion and vasopressin was markedly impaired in ten
polyuric patients (see Table 2). Severe polyuria (more
than 6 liters/day) was unresponsive to trials of va-
sopressin and chlorpropamide, but improved with
chlorothiazide therapy (see Fig. 2).
Role of polydipsia in lithium-induced polyuria.
While recently reviewed evidence in experimental ani-
mals [17] indicates that lithium may directly stimu-
late thirst, observations in humans do not support a
primary role for thirst stimulation in the genesis of
severe lithium-induced polyuria. Thus, four of ten
patients with severe lithium-induced polyuria failed
to concentrate their urine above plasma osmolality
Patient
No.
Umax
14 to 18 hr
dehydration
Umax
dehydration +
vasopressin
Uoem
%
changea
Pogm
before
vasopressin
1
2
3
4
5
6
7
8
9
10
180
172
265
247
377
423
623
471
507
526
288
214
210
291
479
668
664
478
585
588
+60
+24
—21
+18
+27
+58
+7
+1
+15
+12
(310)
(304)
(305)
(295)
(299)
(290)
(29.1)
(312)
(292)
(290)
379±49 466±57 298±2.7
despite prolonged dehydration and vasopressin ad-
ministration [I], whereas patients with psychogenic
polydipsia concentrate their urine above plasma with
prolonged dehydration [11]. Unlike patients with
primary psychogenic polydipsia, in whom prolonged
vasopressin therapy results in concentrated urine and
occasionally in water intoxication [18], patients with
lithium-induced polyuria failed to reduce their poly-
uria or increase their urine osmolality after four days
of treatment with vasopressin tannate in oil (see Fig.
Table 2. Umax in patients with lithium-induced polyuria
Percent change in Uo,m comparing dehydration and vasopressin
to dehydration only. Poem = plasma osmolality; Uoem = urine
osmolality. Reprinted with permission from (1).
Vasopressin
tannate
Control Chior-
propamide
Chioro-
thiazide
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Days: 1-4 5-8 9-13 14-21
Fig. 2. Effect of treatment with vasopressin tannate. chiorpropamide
and chiorothiazide on urine volume and (loom in three patients with
lithium-induced diabetes insipidus. Values are mean + SEM. (Re.
printed with permission from [1].)
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2). Additionally, lithium-induced polyuric patients
reduced their urine volume and increased their urine
osmolality after chlorthiazide administration [1, 19].
These actions of chlorthiazide are expected in neph-
rogenic diabetes insipidus [20, 21] but not in psycho-
gic polydipsia [22]. While stimulation of thirst may
contribute to the total water intake, these studies
indicate a primary nephrogenic basis for lithium-in-
duced polyuria in humans. Further work is necessary
to determine the importance and the mechanism of
thirst stimulation in several forms of nephrogenic
diabetes insipidus, including those induced by hyper-
calcemia, hypokalemia and lithium.
Role of central diabetes insipidus in lithium-induced
primary polyuria. Several patients [1, 12] with lithium-
induced polyuria have shown significant increases
in urine osmolality when exogenous vasopressin is
administered after fluid deprivation, indicating that
lithium may cause a partial central diabetes insipidus
in occasional patients. The mechanism of action
is unknown, but may relate to interference with the
catecholamine-activated adenylate cyclase involved
with ADH release [23, 24].
Role of kidney in lithium-induced primary polyuria.
a. ADH-independent mechanisms. Since the polyuria
of hypokalemia and hypercalcemia can be explained
in part by reduction in the osmotic gradient in the
renal medulla secondary to impaired transport of
sodium chloride, the effect of lithium on the corti-
comedullary sodium gradient was investigated in
early studies. In the rat [1] and the dog [25], lithium
does not significantly affect the normal corticomed-
ullary gradient for sodium. In addition, free water
clearance is normal in rats [26] and in human subjects
[12] with lithium-induced polyuria, indicating that
sodium chloride reabsorption in the ascending limb
Time, rn/n
Fig. 3. Effect of acute lithium chloride infusion (0.037 M) on frac-
tional urine flow in Brattleboro rats undergoing water diuresis. Con-
trol animals received 0.037 M NaCI-D,W infusion throughout the
experiment.
of Henle's loop and the distal convoluted tubule is
grossly normal.
It has recently been reported that Brattleboro rats
with congenital absence of ADH become more poly-
uric after lithium treatment [27, 281. To differentiate
between primary stimulation of thirst and an ADH-
independent renal mechanism for this increased poly-
uria, Rahn and Forrest [29] studied the effect of acute
lithium administration (plasma lithium concentra-
tion, 1.2 mEq/liter) on the renal excretion of water in
the anesthetized Brattleboro rat. Following estab-
lishment of a steady-state water diuresis, administra-
tion of lithium resulted in marked increases in V and
CH2O/glomerular filtration rate (GFR), without a sig-
nificant change in Coam (Fig. 3). Since ADH is en-
tirely absent in this rat species, these increases in-
dicate that an important ADH-independent factor in
lithium polyuria is the impairment of sodium and
water reabsorption in proximal segments of the neph-
ron; the increased delivery of this solution to the
ascending limb of Henle's loop and distal convoluted
tubule increases the generation of free water. Fur-
thermore, the capacity of the ascending limb to in-
crease markedly electrolyte-free water formation fol-
lowing increased distal delivery of water and salt is
additional evidence that medullary sodium chloride
transport is not impaired by lithium.
b. ADH-dependent mechanisms. In the majority of
studies, lithium impaired the action of ADH to stim-
ulate osmotic water flow in animal models, including
the rat in vivo [1, 28, 30, 31] and the toad urinary
bladder [12, 30, 32]. In a single study, Bentley and
Wasserman [33] were unable to detect lithium-in-
duced inhibition of ADH-stimulated water flow in
toad urinary bladders. Both whole animal and toad
urinary bladder models have been utilized to deter-
mine if lithium-induced inhibition of ADH occurs
proximal or distal to the formation of intracellular
AMP.
In the toad urinary bladder, a mucosal lithium
concentration of 11 mEq/liter significantly inhibited
ADH-induced water flow but had no effect on water
flow induced by 1.0 mivi dibutyryl cAMP [12], suggest-
ing inhibition proximal to cAMP generation. While
Harris and Jenner [30] reported that 2.0 mM serosal
lithium inhibited the water flow response in toad
urinary bladders exposed to 1.1 mrvi cAM P, Singer and
Franko [32] found no effect on dibutyryl cAMP-
induced water flow at serosal lithium concentrations
up to 11 mEq/liter. In in vivo studies in the rat,
Forrest et at [1] observed that lithium-induced poly-
uria was not interrupted by brief i.v. doses of vaso-
pressin or dibutyryl cAM P. (These doses were capable
of reversing a water diuresis and producing a concen-
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trated urine in both normal and Brattleboro rats with
hereditary diabetes insipidus.) This inhibition was
virtually complete following ADH administration,
whereas there was a modest increase in osmolality to
levels below that of plasma following administration
of dibutyryl cAMP (Fig. 4). Martinez-Maldonado et
a! [34] have recently confirmed that chronic lithium
administration impairs the urinary response to ex-
ogenous dibutyryl cAMP in the rat. Thus, phys-
iological studies with both toads and rats have
yielded evidence suggesting that lithium impairs the
action of ADH at steps both proximal and distal to
cAMP formation.
Extensive biochemical studies have also indicated
that lithium affects ADH-stimulated cAMP forma-
tion and utilization. When lithium is added in vitro
to homogenates of renal medulla obtained from
both humans and animals [28, 3 5—38], ADH-induced
adenylate cyclase activity is inhibited. Dousa and
Hechter [37] have shown that this inhibition is non-
competitive, and is enhanced in the presence of high
concentrations of renal medullary solutes (NaCI and
urea). While human renal medullary phosphodiester-
ase activity is not affected by lithium, Dousa [36]
has reported a modest but significant impairment of
cAM P-dependent protein kinase activity, indicating
impairment of cAMP utilization.
In summary, both physiological and biochemical
investigations have demonstrated that lithium im-
pairs ADH action at steps both proximal and distal to
cAMP formation. However, in in vivo rat studies and
in vitro toad bladder studies, and in cyclic nucleotide
assays, lithium inhibition of ADH actions has been
Uosm (± SEM) after vasopressin
U0, (± SEM) after d b cAMP
.T
150 600 1200 (mg/day)
Group A B c DMC dose
Fig. 5. Concentrating ability in demeclocycline (DMC)-treated pa-
tients. The three dosage groups are identified on the abscissa,
and the ordinate shows the maximal urine osmolality (max Uo,m)
for individual patients in each group, The mean for each group is
indicated, as is the lower limit for normal controls (dashed line).
Each point represents a single patient (total: N = 24 patients)
studied after six weeks of demeclocycline therapy, except group C.
These five patients (group C; 1200 mg/day) were studied when they
became symptomatic: one patient at one week, two patients at
three weeks and two patients at six weeks. (None of these five
patients were studied prospectively; the group B patients are dis-
cussed in the text.) (Reprinted with permission from [2].)
easier to demonstrate than lithium inhibition of
cAMP actions.
Tetracyclines
The tetracycline (TCN) class of antibiotics has
been in use for sometime, but the potential for some
of them to interfere with renal water metabolism has
been recognized only with the recent use of relatively
large doses of certain members of this class [2, 12,
39]. For example, polyuria and polydipsia were
prominent side effects in patients treated for acne
with very large doses of demeclocycline (demethyl-
chlortetracycline, DMC). The results of standard 12- to
14-hr water deprivation tests are shown in Fig. 5 for a
group of 24 such patients treated with DMC doses
ranging from 150 to 1200 mg/day. These patients
developed a dose-related defect in maximum con-
centrating ability, which was uniformly produced at
the highest dose studied (1200 mg/day). At inter-
mediate doses (600 mg/day) the defect did not appear
in every patient, and was partial in some. In contrast to
occasional patients with lithium-induced diabetes in-
sipidus [1, 12], none of the patients with severe DMC-
induced diabetes insipidus responded significantly to
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Fig. 4. Maximum effect of single i.v. injection of vasopressin (5 to 10
mU/kg) and dibutyryl (db) cyclic AMP (15 to 20 mg/kg) on U0.,.
during water diuresis in normal, hypothalamic diabetes insipidus
(Brattleboro St rain) and lithium-polyuric rats. Values are mean
SEM. (Reprinted with permission from [I].)
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• Patient 5
U Patient 6
Fig. 6. ADH response in patients with DMC-induced diabetes insip-
idus. Three of the patients in group C (1200 mg/day) were given
exogenous ADH (aqueous vasopressin: Pitressin, Parke, Davis &
Co., Detroit, Michigan) after a 14-hr water deprivation test. The
maximum urinary osmolality (Uoim) after water deprivation alone
is shown on the left for each patient; that obtained after subsequent
ADH administration is shown on the right. There was no signifi-
cant difference in Uo.m before and after ADH administration,
demonstrating nephrogenic diabetes insipidus. (Reprinted with
permission from [2J.)
exogenous ADH (Fig. 6). Therefore, these patients
have dose-dependent partial or complete nephrogenic
diabetes insipidus.
The site of the defect in water conservation in these
patients (Table 1) was evaluated by the standard
clearance methods described earlier. Since BUN con-
centration, Ccr, Umin and CH2O were all normal under
appropriate test conditions [2], there were probably
no gross defects in the generation and maintenance of
an osmotic gradient. Therefore, the physiological de-
fect in the water conservation mechanism probably
lies between ADH and the collecting duct response to
ADH. According to the mechanisms already dis-
cussed (Fig. 1), the failure to respond appropriately
to exogenous ADH suggests defects with cAM P gen-
eration, metabolism or action. Unfortunately, these
possibilities cannot be examined in vivo in humans.
As in the lithium studies, the toad urinary bladder
was used as an in vitro model to investigate this form
of drug-induced diabetes insipidus. ADH-induced os-
motic water flow in this model system is clearly inhib-
ited (over 50%) by DMC in a dose-responsive and
reversible manner similar to that seen in humans [2].
In contrast to lithium, DMC is a more effective inhib-
itor of ADH action in toad urinary bladders when the
antibiotic is present in the serosal medium, and DMC
may not have other important effects on electrolyte
metabolism in humans. Since both AD H-induced
and cAMP-induced water flow are inhibited in this
model system, it appears that DMC has some in-
hibitory effects beyond adenylate cyclase and cAM P
generation. At low doses of DMC, all of the inhib-
ition of ADH-induced water flow can be explained by
inhibition of cAMP-action; however, at high doses of
DMC there is progressively greater inhibition of
the ADH response, without further inhibition of the
cAMP response (Fig. 7). These observations suggest
that DMC interferes with cAMP generation, as well
as with cAMP action. The former possibility was
directly examined in human renal medulla [40]; when
adenylate cyclase activity was measured in an in vitro
assay system, DMC was found to produce significant
inhibition of cAMP generation. Moreover, DMC in-
hibited cAMP-dependent protein kinase in this in
vitro system (Fig. 8). Acceleration of cAMP metabo-
lism or interference with other cAM P actions or both
were not examined. Therefore, physiological and bio-
chemical evidence suggests that DMC inhibits ADH-
induced water flow at least at two different sites.
However, there are certain problems in relating the
biochemical findings concerning DMC to the phys-
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Fig. 7. Bar graphs (mean SEM) relating dose of DMC to inhi-
bition of water flow (W) induced by A DH (hatched bars) and cAMP
(open bars). Significant inhibition was observed at each dose (P <
0.05 or better; N = 6 to 8 in each group) except for DMC = 0.05
mg/mi, for ADH. (Reprinted with permission from [42].)
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iological observations. For example, other tetracy-
dines (tetracycline, chlortetracycline) are effective in
inhibiting cAMP-dependent protein kinase in human
renal medulla, but have not produced clinically ap-
parent nephrogenic diabetes insipidus in humans.
(Tetracycline does produce a small impairment of
urinary concentrating ability [4].) Therefore, the ef-
fects of several different tetracyclines on ADH-in-
duced osmotic water flow were examined in toad
urinary bladders [42]. Tetracyclines with different
chemical structures and properties were chosen to
identify those characteristics which are responsible
for inhibition of ADH action. Although the five tet-
racyclines studied share a common four-ring core
structure, they differ (by virtue of side-chain sub-
stitutions) in three major properties: lipid solubility,
calcium chelating ability and serum protein binding.
Each of these properties may be physiologically im-
portant: lipid solubility probably determines pene-
tration of the drug into the cell [43], calcium is
an important determinant of epithelial water per-
meability [44] and membrane phosphoproteins may
be critical effectors of ADH action [45, 46].
The results showed a strong correlation between
serum protein binding and inhibition of ADH-in-
duced osmotic water flow. There was no correlation
between any other physico-chemical property and
either ADH-induced or cAMP-induced water flow. It
was subsequently shown that DMC binds specifically
to toad bladder epithelial cell proteins [42], with mo-
lecular weights of the order of 100,000 daltons (Cox
and Singer, unpublished observations). Thus, DMC
appears to cause nephrogenic diabetes insipidus, at
least in part by binding to a specific epithelial cell
protein which is important in the action of ADH.
These clinical and experimental observations also
have important therapeutic implications. It has re-
cently been suggested that lithium might be useful in
the treatment of the syndrome of inappropriate ADH
secretion [47], although such treatment carries the
risk of lithium intoxication in sodium-depleted pa-
tients [2]. On the other hand, DMC has success-
fully been used to treat patients with tumor-induced
inappropriate ADH secretion [48, 49], and has no
known important interrelationships with human so-
dium metabolism. An example of such a case is
shown in Table 3 (Cox and Singer, unpublished ob-
servations). Ideally, a strongly protein-bound tet-
racycline derivative, without antibiotic or phototoxic
properties, should be developed as a specific ADH
antagonist for use in certain hyponatremic states,
such as those associated with tumors. Such an agent
may be used to induce dose-related partial nephro-
genic diabetes insipidus, and thus could allow much
more liberal electrolyte-free water intake. (If the
thirst mechanism is normal, symptomatic excessive
water losses induced by DMC would be replaced
orally until the drug dose is reduced.)
Methoxyflurane
Shortly after the introduction of this general anes-
thetic agent, Paddock, Parker and Guadagni [4] de-
scribed three patients in whom severe renal failure
developed after receiving methoxyflurane. Post-
operative polyuria associated with a toxic nephrop-
athy was described two years later in 17 of 94
patients who had received methoxyflurane [3]. Nu-
merous subsequent studies have attributed renal dys-
function of the polyuric type to this anesthetic, al-
though several patients with oliguria have been
reported. Mazze, Shue and Jackson [50] evaluated
renal dysfunction in a randomized prospective study
of 22 men receiving either methoxyflurane or halo-
thane anesthesia. All 12 patients receiving methoxy-
flurane had some evidence of renal dysfunction, in-
cluding six with polyuria and dehydration in the
postoperative period. Those patients receiving me-
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Fig. 8. Effects of increasing conceiu rat fons of demeclocycline
(DMC) on enzymes from human renal medulla. •—• = ADH-
stimulated adenylate cyclase activity; 0—— —o = cyclic AMP
phosphodiesterase activity; X— — —x = cyclic AM P-stimulated
protein kinase activity. (Reprinted with permission from DOUSA 1:
Mayo C/in Proc 49:188—199, 1974.)
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Table 3. Treatment of excessive ADH secretion with demeclocycline
Dehydration test
Urns,,; mOsm/kg Water loading test
Water load
Before ADH After ADH Ui,,,,,, mOsm/kg excreted, % CM,O, mi/mm
BeforeDMCadministration 900 905 888(8hr) 15%(8hr) —1.01 (8hr)
After one week of DMC
administration 270 247 l84(2hr) 70%(4hr) l.68(2hr)
After withdrawal of DMC
foroneweek 422 450 446(2hr) 15%(4hr) 0.00(2hr)
After withdrawal of DMC
forthreeweeks 648 657 596(2hr) 18%(4hr) —0.09(2hr)
Maximum urinary concentrating ability (Urns,,) was studied after standard 14-hr water deprivation tests (before and I hr after i.v.
administration of ADH (200 mU of aqueous vasopressin)). Standard water loading tests (20 mI/kg = 800 ml) were done to measure the
minimum urine osmolality (Umi), the percent of the water load excreted and the electrolyte-free water clearance CH,O. The patient
was a 73-yr-old man with inoperable, biopsy-proven Oat cell carcinoma of the lung, and was treated with demeclocycline (DMC, 900
mg/day) for symptomatic hyponatremia. The symptoms were relieved within three days of therapy, recurred when therapy was with-
drawn and disappeared when DMC was reinstituted after conclusion of the protocol above, (From Cox and Singer, unpublished
observations.)
thoxyflurane had significant increases in serum con-
centrations of sodium, uric acid and BUN, and in
plasma osmolality; they also demonstrated marked
weight loss associated with their impaired renal con-
centrating ability. In a review of 104 patients with
postoperative renal dysfunction attributed to me-
thoxyflurane, acute polyuria was noted in 74 patients,
but oliguria was seen in 10 patients [51]. There were
14 deaths among the polyuric patients, 5 of whom
had required dialysis. In 26 of the 60 survivors, the
duration of the vasopressin-resistant polyuria was 7
to 28 days.
Oxalic acid and inorganic fluoride are two metabo-
lites of methoxyflurane which have been implicated in
the nephrotoxicity seen with this agent, but each has
been associated with a different syndrome. In pa-
tients developing oliguric renal failure after exposure
to methoxyflurane, urinary excretion of oxalate is
markedly increased, often with extensive oxalate dep-
osition in the renal medulla. These histologic abnor-
malities are similar to those seen following ethylene
glycol-induced acute renal failure (3 to 10% of ethyl-
ene glycol is metabolized to oxalic acid [52]), and
consist of deposition of calcium oxalate crystals in
the tubular lumens and epithelial cells, inflammatory
exudates, degenerative changes and interstitial ed-
ema.
In contrast, the polyuric state induced by methoxy-
flurane is related to the marked increase in the se-
rum concentration and urinary excretion of inorganic
fluoride [53—55]. Serum inorganic fluoride concentra-
tions peak on the first or second postoperative day
(following methoxyflurane), and the level achieved is
directly related to the amount of anesthetic adminis-
tered [56]. In several studies [55—57] a concentration
of more than 90 imoles/liter has been associated
with polyuria, whereas lower levels are not associated
with renal dysfunction. A similar vasopressin-resis-
tant polyuria has recently been demonstrated in rats
given sodium fluoride [58]. To our knowledge, the
effect of fluoride (or methoxyflurane) on CH2O and
TCH2O has not been formally investigated in hu-
mans or in rats, but some information is available
on the effects of sodium fluoride on CH2O, TCH2O
Umax and corticomedullary sodium gradient in the
dog. During steady-state mannitol diuresis, infusions
of sodium fluoride resulted in an increase in flow and
a reduction in TCH2O while GFR and UNaV remained
stable [59]. Sodium fluoride was consistently without
effect on CH2O or the ratio CH2O/V during hypotonic
sodium chloride diuresis. These studies have been
interpreted to suggest that sodium fluoride does not
grossly impair ascending limb sodium chloride trans-
port, but may cause nephrogenic diabetes insipidus,
either by washing out the medullary solute (since
fluoride is a vasodilator in many vascular beds) or by
reducing the collecting duct permeability. In a single
study comparing the effects of methoxyflurane and
halothane on vasopressin-stimulated water flow in
the toad bladder [60], both agents impaired vasopres-
sin-stimulated water flow with little or no effect on
vasopressin-stimulated urea movement.
Sulfonylureas
The antidiuretic properties of the sulfonylurea,
chlorpropamide, were first described in 1966 [61];
those of tolbutamide were described in 1969 [62].
There have been many studies of the antidiuretic
properties of the various sulfonylureas since that time
(see [63] for references), but chlorpropamide remains
the most well-studied orally administered hypogly-
cemic drug with antidiuretic properties [64]. Most of
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the in vivo and in vitro studies of chiorpropamide
suggest at least two modes of action: increased release
of endogenous antidiuretic hormone [65] and en-
hancement of the renal effects of submaximal levels
of ADH [II, 66, 67]. In contrast, some recent studies
[68] have not found any increase in endogenous
plasma ADH (arginine-vasopressin) concentrations
following chiorpropamide administration to patients
with pituitary diabetes insipidus, and attribute all of
the antidiuretic properties of these agents (as well as
those of clofibrate and carbamazepine) to enhance-
ment of peripheral ADH actions. These authors attri-
bute the paradoxical water diuresis following ex-
ogenous lysine-vasopressin administration to recep-
tor site interactions between the drugs and the hor-
mones.
However, in 1971 Radô and Borbély reported that
not only did a new sulfonylurea (glybenclamide,
glyburide) lack any antidiuretic properties, but this
agent actually caused polyuria [6]. This surprising
effect has prompted several studies of the effects of
other sulfonylureas on water metabolism, but glybu-
ride remains the best studied sulfonylurea with '4diu-
retic" properties. Therefore, direct comparisons of
chlorpropamide and glyburide actions in vivo and in
vitro are essential to an understanding of how sul-
fonylureas affect water metabolism.
Radó and Borbély [69] evaluated the mechanism of
glyburide-induced diuresis with studies of osmolar
(Com) and solute-free water clearances. Patients with
central pituitary diabetes insipidus were treated with
glyburide (20 to 30 mg daily), and developed a poly-
uria of nearly double their baseline rate, with little
change in C0Rm; a significant (30%) decrease in Uoam;
and an insignificant (6%) increase in GFR (estimated
by Ccr), These changes reverted to the baseline level
when the drug was discontinued and reappeared
when the drug was reinstituted. The effects of sub-
maximal doses of ADH (0.04 to 2.0 ig of DDAVP)
were evaluated in similar patients with central diabe-
tes insipidus before and after glyburide (5 to 15 mg
daily) administration [70]. The Uoem was significantly
lower and solute-free water clearances significantly
higher in glyburide periods than in control periods
without glyburide. Studies of electrolyte-free water
clearance were not performed. Increasing the dose of
ADH decreased the magnitude of the glyburide effect
and delayed the time at which a significant difference
between glyburide and control periods appeared. In
general, the glyburide findings were reproduced by
Moses, Howanitz and Miller in 1973 [63] and by
Radó et al in 1974 [71] in normal subjects. Similar
findings also have been obtained with two other sul-
fonylureas: tolazamide [63, 72] and acetohexamide
[63]; see Table 4. These data suggested that glyburide
and other diuretic sulfonylureas have a peripheral
(renal) action to decrease ADH effectiveness at sub-
maximal doses of ADH.
However, this mechanism alone cannot explain
glyburide's induction of increased water excretion in
water-loaded normal volunteers or patients with cen-
tral diabetes insipidus, circumstances when endoge-
nous ADH concentrations should be minimal or ab-
sent [73]. Furthermore, Fernandez and Singer [5]
have observed that when glyburide (0.4 zg/ml) is
added to the serosal aspect of the toad urinary blad-
der (Fig. 9), whether added before or after ADH, this
diuretic sulfonylurea enhances the water flow induced
by submaximal doses of ADH (0.25 to 0.5 mU/mI),
In this respect, glyburide has essentially the same in
vitro actions as chlorpropamide, the paradigm an-
tidiuretic sulfonylurea. In addition, neither drug has
any effect on osmotic water flow in the absence of
ADH or in the presence of maximal doses of ADH;
paradoxically, both drugs inhibit the effects of cAM P
on osmotic water flow. Finally, the fact that glybu-
ride has a diuretic effect in the Brattleboro rat (which
lacks endogenous ADH) also implies that another
mechanism must be operative [63, 73].
While it is clear that the diuretic sulfonylureas
Table 4. Influence of four sulfonylurea drugs on ability of normal subjects to excrete a maintained water loads
Urinary osmolality
mOsm/kgH20
Urine volume
mi/mm
Water clearance
mi/mm
Osmolal clearance
mi/mm
No drug 62.2 2.5 15.7 0.8 12.4 0.7 3.34 0.14
Chlorprppamide(27) 92.7 g8b 12.6 0•9b 91 08b 3.54 0.18
No drug 68.6 4.0 15.1 0.9 11.5 + 0.9 3.61 + 0.25
Tolazamide(13) 55.9 44b 18.6 15b 15.0 14b 3.62 0.18
No drug 69.0 3.4 16.3 + 1.1 12.4 + 0.8 3.98 0.37
Acetohexamide (7) 60.7 37c 19.4 1.5 15.2 + l.2 4.15 0.40
Nodrug 62.9 2.6 17.0 0.7 13.2 0.6 3.72 0.18
Gyburide(14) 549 3Øb 20.8 16.8 10b 3.97 0.25
Numbers indicate mean SEM. In parentheses are the numbers of subjects in each group. Reprinted with permission from [63].
<0.01.
P < 0.05.
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Glyburide ADH peak 60' after ADH Glyburide
S •
Fig. 9. Enhancement of ADH-induced water flow by glyburide. The
water flow (.sl/min) for eight paired toad urinary hemibladders is
indicated on the ordinate. After a stable baseline period, glyburide
(0.4 tg/ml) was added (left) to the serosal medium for the experi-
mental hemibladders (dashed line). The resulting water flows (mean
SUM) are compared with their corresponding control hemiblad-
ders (solid line) before and after administration of a submaximal
dose of ADH (0.25 mU/mi). Before ADH administration (left),
there is no difference between glyburide-treated (open circles) and
control (solid circles) groups. There is significant enhancement of
the ADH response, both at the peak ADH response ( = 13.3 +
1.1 tl/min; P <0.01) and 60 mm aftertheADH response( = 8.6
0.8 121/mm; P < 0.01). Note that when glyburide was added to
the control group (in the presence of ADH) at the end of the
experiment (right), a significant enhancement of water flow was
observed ( = 20.3 + 1.1 121/mm; P < 0.001). (Reprinted with
permission from [5].)
must have actions which do not include inhibition of
ADH effects, it is less obvious how these drugs can
cause a diuresis. Since glyburide has no effect in
patients with nephrogenic diabetes insipidus [71], a
renal mechanism is probable. Radó and Borbély [69]
failed to demonstrate any increase in sodium or po-
tassium excretion in glyburide-treated patients with
pituitary diabetes insipidus. Moses et al [63] used
hydrated normal subjects and also found that glybu-
ride did not change total solute, sodium, potassium
or excretion. However, Tuma, Syzlman and Better
[72] did find that tolazamide decreased filtration frac-
tion and lowered the minimum Uosm. There was also
a slight decrease in potassium excretion, although no
change in sodium excretion was observed. Neither of
the latter groups observed a change in GFR, and
plasma glucocorticoid concentrations were normal
after glyburide treatment. In contrast to these find-
ings, Foy and Lucas [74] recently reported that the
acute, but not chronic, administration of large doses
of chiorpropanide or glyburide can increase a wa-
ter diuresis in rats. A water diuresis could be de-
creased by acute administration only of large doses of
tolbutamide, but could be decreased by chronic ad-
ministration of lower doses of either chlorpropamide
or glyburide. The authors attribute the differences
between acute (high dose) and chronic (low dose)
findings to different levels of submaximal ADH activ-
ity, and consequently of sulfonylurea sensitivity, in
the two experimental conditions. If these data are
confirmed, it appears that even the paradigm sul-
fonylurea, chlorpropamide, can cause a water diuresis
under some circumstances. Furthermore, Foy and
Lucas [74] found that acute chlorpropamide adminis-
tration increased sodium excretion, and that acute
administration of either chlorpropamide or tolbuta-
mide decreased urinary potassium excretion. Al-
though the authors suggest that antimineralocorti-
coid activity may account for the change in po-
tassium excretion, a role for the insulin released by
the sulfonylureas was not considered.
The above data suggest the following mechanism
for sulfonylurea-induced diuresis. Without a signifi-
cant change in GFR, there may be decreased prox-
imal reabsorption of salt and water, and increased
distal reabsorption of the delivered salt. In the ab-
sence of significant ADH effects, the delivery of this
dilute, relatively electrolyte-free water to the collect-
ing ducts will result in the excretion of an increased
volume of urine with a lower minimum Uom and
relatively little or no perceptible change in solute or
electrolyte excretion (perhaps with a slight decrease
in Na/K ratio).
It is interesting to contrast the actions of chlor-
propamide. (the "antidiuretic" sulfonylurea) and
glyburide (the "diuretic" sulfonylurea). Both agents
enhance the effects of submaximal doses of ADH on
water flow in vitro, but only chlorpropamide may
cause increased central release of ADH. Therefore,
the water retention induced by chronic chlorpropa-
mide administration in humans may be more related
to increased central releaseof ADH than to increased
peripheral sensitization to ADH, although the latter
effect may also play a role. Although the peripheral
sensitization to ADH may be related to inhibition of
phosphodiesterase activity [75], such a mechanism
could not explain the inhibition of cAMP action.
Alternatively, if chlorpropamide decreased trans-
membrane cAMP permeability in both directions,
enhancement of ADH and inhibition of cAMP (ex-
ogenous) actions might be expected. However, Fich-
man and Brooker [76] reported increased cAMP ex-
cretion after chlorpropamide administration.
On the other hand, only chronic glyburide admin-
istration increases water excretion in humans, pre-
sumably by increasing sodium and water delivery to
the distal diluting sites. This may be a direct effect of
the drug, or may result from insulin release causing
sodium retention and volume expansion. In the latter
case, any such delivery effects of chronic chlorpropa-
mide administration must be outweighed by increased
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ADH release. Further studies of these agents are ob-
viously required before a definitive mechanism of
action can be established for the diuretic actions of
the sulfonylureas.
Miscellaneous drugs
Propoxyphene. A single case report of ADH unre-
sponsiveness to polyuria secondary to dextropropoxy-
phene intoxication has appeared [77]. The possible
roles of hypokalemia (which was present) and hyper-
calcemia (which was not determined) in the devel-
opment of nephrogenic diabetes insipidus in this case
were not excluded. The effects of propoxyphene were
subsequently studied in toad urinary bladders at
doses (10 to 25 sg/ml) thought to be comparable to
those achieved in the kidney [7]. Both dextro- and
levopropoxyphene were found to produce small,
but significant decreases in the osmotic water flow
induced by submaximal doses of ADE-l (5.0 mU/mI).
The clinical significance of these findings at the u3ual
therapeutic levels of propoxyphene is uncertain. This
narcotic drug would probably not be useful in the
treatment of syndromes associated with excessive
ADH secretion because it carries addicting potential,
and also may interfere with the action of other nar-
cotic analgesics in patients with tumor-associated ex-
cessive ADH secretion.
Isophosphamide. Isophosphamide is a derivative of
cyclophosphamide, and has been reported to cause
nephrogenic diabetes insipidus along with other
proximal and distal tubular defects in a patient
treated for breast cancer [78]. Isolated proximal
tubular defects have also been observed after treat-
ment with this antineoplastic agent. In contrast, how-
ever, the parent compound (cyclophosphamide) and
other antineoplastic agents have been associated with
water intoxication, presumably due to increased re-
lease or peripheral action of ADH [79].
Coichicine and the ymca alkaloids. Colchicine and
other agents which disrupt intracellular microtubules
(such as the ymca alkaloids) interfere with the action
of ADH in toad urinary bladders [80]. These agents
inhibit water flow responses to both ADH and to
cAMP, without altering their stimulatory actions on
sodium transport. Subsequently, it was shown that
although ADH- and cAMP-mediated water flows
were inhibited by either colchicine or vinblastine in
rats, these drugs had no effect on adenylate cyclase,
cAMP phosphodiesterase or cAMP-dependent pro-
tein kinase obtained from subcellular fractions of rat
renal medulla [81]. The results localize the drug-in-
duced defects in ADH responsiveness beyond cAMP
generation. Similar defects in ADI-1 responsiveness
have not been reported with the use of these agents in
humans. In fact, vincristine (another of the ymca
alkaloids) has caused hyponatremia and water reten-
tion [82,83], probably by increasing ADH release
[84], an affect which may be the result of alterations
in hypothalamic microtubules [85].
Vasopressinoic acid. Vasopressinoic acid is a struc-
tural analog of arginine vasopressin, which has not
been used clinically. This agent inhibits the antidiu-
retic action of vasopressin in vivo, and blocks the
stimulation of renal medullary adenylate cyclase by
vasopressin in vitro; however, this agent does not
inhibit hormone-stimulated adenylate cyclase ob-
tained from other tissues [86]. These observations
suggest that this agent blocks a specific receptor site
for vasopressin.
In summary, a variety of pharmacological agents
have been demonstrated to cause nephrogenic diabe-
tes insipidus by diverse and incompletely understood
mechanisms. We have summarized the primary renal
effects of these agents in humans in Table 5. Exten-
sive earlier work on the renal concentrating defects
associated with hypokalemia and hypercalcemia at-
tributed these defects to reduction in corticomed-
ullary solute gradient and/or to direct interference
with ADI-1-stimulated water transport in the collect-
ing ducts. Present evidence indicates that both defects
occur in these electrolyte disorders. In contrast, data
from clearance studies suggest that the diabetes insip-
idus resulting from lithium, demeclocycline or so-
dium fluoride is not associated with gross impairment
of NaCl reabsorption in the renal medulla (as esti-
mated by C1120). These forms of nephrogenic diabetes
insipidus result primarily from impairment of ADH-
stimulated water transport. Micropuncture studies of
Table 5. Primary renal effects of electrolyte- and drug-induced
disorders which may impair ADH responsiveness
Human studies Polyuria
ADH-
induced
water flow
Salt
transport
(CH,o)
Cyclic
AMP
formation"
Electrolyte
disorders
Hypokalemia NDI I ?(j) ?( )
Hypercalcemia ND! I I ?(j)
Drug-induced
disorders
Lithium NDI,?CDI 0 1
Demeclocycline NDI 1 0
Methoxyfiurane ND! I ?(O) ?
Glyburide I I I ?(I)
Isophosphamide NDI I I ?
Propoxyphene 0 1 0 ?
Colchicine 0 ?(j) ?(0) ?(0)
a ND! = nephrogenic diabetes insipidus; CDI = central diabetes
insipidus; I = increased; 0 = no change; = decreased;
= unknown or uncertain; ( ) = animal studies.
b Measured in human renal tissue in vitro (or by urinary excretion
of cyclic AMP).
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stimulated water transport. Micropuncture studies of
the papillary tip in the hamster (which previously
demonstrated no osmotic disequilibrium between
collecting duct urine and adjacent vasa rectae plasma
in a hypokalemic model of nephrogenic diabetes in-
sipidus [87]) might provide direct evidence con-
cerning impaired collecting duct permeability in these
drug-induced models.
Two agents, lithium and glyburide, appear to in-
crease water excretion by impaired reabsorption of
the glomerular filtrate in the proximal portions of the
nephron, with enhanced delivery of solute and water
to the diluting segments. It is now apparent that
lithium causes severe nephrogenic diabetes insipidus
by the unique combination of increased delivery of
filtrate to the distal tubule and collecting duct with
impaired ADH-stimulated water reabsorption. In
contrast, since collecting duct responsiveness to
ADH (and presumably to cAMP) is intact or en-
hanced following treatment with sulfonylureas, clini-
cal nephrogenic diabetes insipidus is not observed,
unless the increased distal delivery is very great.
Considerable evidence indicates that the impaired
ADH-induced water flow following lithium, deme-
clocycline or NaF administration is related to defec-
tive ADH-induced cAMP generation and utilization;
it is not yet possible to determine with certainty the
specific intracellular step(s) at which each of these
agents impair the physiological response. These un-
certainties may account for the different results ob-
tained from some in vivo and in vitro studies of
lithium action. The paradoxical effects of the sul-
fonylureas on water flow in in vivo and in vitro
systems relate to opposing actions on the proximal
and distal portions of the nephron. Thus, these agents
may increase urine flow by decreasing proximal reab-
sorption or may decrease urine flow by increasing
distal water reabsorption.
Both lithium [47] and DMC [48] have recently
been suggested to be therapeutic agents for the treat-
ment of the chronic syndrome of inappropriate ADH
secretion (SIADH). From information currently
available, it is clear that DMC is preferred because it
produces dose-related inhibition of ADH action (as
opposed to the variable response following lithium
administration) and DMC avoids the central nervous
system effects of lithium in patients with symptomatic
hyponatremia. It is important to stress that the role
of DMC in the very long-term treatment or in the
emergency treatment of hyponatremia in SIADH has
not yet been assessed. Present emergency therapy for
hyponatremia associated with impaired central ner-
vous system function remains water restriction and
treatment with i.v. administered diuretics while uri-
nary electrolytes are replaced [88].
Continued study of these agents should permit de-
velopment of improved pharmacologic approaches to
diverse defects in water metabolism and should con-
tribute further to uncovering the specific steps in-
volved in the mediation of ADH action. Such studies
will eventually lead to the circumvention of drug side
effects which produce diabetes insipidus as well as to
the utilization of less toxic agents to treat SIADH
and other forms of hyponatremia.
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